Form 4: Ginkgo Bioworks Director Christian Henry Reports Significant Equity Transactions

Ginkgo Bioworks Holdings, Inc. Director Christian O. Henry reported the conversion of 10,822 restricted stock units into Class A shares and the grant of 34,375 new stock options.

Summary

• Christian O. Henry, a Director of Ginkgo Bioworks Holdings, Inc. (DNA), filed a Form 4 detailing recent equity transactions.
• On June 11, 2025, 10,822 Restricted Stock Units (RSUs) vested and were converted into an equal number of Class A Common Stock shares. These RSUs were granted on June 13, 2024, and vested fully prior to the company's Annual Meeting of Shareholders.
• Following the RSU conversion, Christian O. Henry directly beneficially owns 44,310 shares of Class A Common Stock.
• On June 12, 2025, Christian O. Henry was granted 34,375 stock options with an exercise price of $9.29 per share.
• These new stock options will vest in substantially equal installments on each of the first three anniversaries of the grant date, becoming fully vested on the third anniversary, subject to continued service as a Non-Employee Director.
• The grant of new stock options is in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Program, which became effective on June 12, 2025.

Sentiment

Score: 7

Explanation: The filing indicates routine equity compensation for a director, including the vesting of RSUs and the grant of new stock options, which aligns the director's interests with shareholder value and reflects ongoing compensation practices.

Positives

• The vesting of 10,822 Restricted Stock Units (RSUs) into Class A Common Stock indicates a successful milestone for previously granted equity compensation.
• The grant of 34,375 new stock options aligns the director's long-term interests with the company's performance and shareholder value, as the options have an exercise price of $9.29 and vest over three years.

Future Outlook

The newly granted stock options will vest in substantially equal installments on each of the first three anniversaries of the grant date (June 12, 2025), subject to the director's continued service.

Industry Context

This filing is a routine disclosure of insider equity transactions and compensation, which is standard practice across publicly traded companies, particularly for directors receiving equity-based compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants to the director align their financial interests with the company's stock performance, potentially encouraging decisions that enhance shareholder value.

Next Steps

• The newly granted stock options will vest in three annual installments, with the first vesting occurring on June 12, 2026, the second on June 12, 2027, and the third on June 12, 2028, assuming continued service.

Key Dates

Keywords

Ginkgo Bioworks, DNA, SEC Form 4, insider transaction, stock options, restricted stock units, director compensation, equity ownership, beneficial ownership